Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

IMV Inc. (T:IMV)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for IMV within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 04, 2019 07:05 ET
IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis Program and director of Wistar’s Melanoma Research Center.
Read full article
Aug 22, 2019 07:05 ET
IMV Inc. to Present at Upcoming Investor Conferences
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that company management will be presenting at the following investor conferences in September:
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.44
--
--
Price to Sales - TTM
406.24
19.72
12.99
Price to Book - most recent quarter
10.15
2.70
2.71
Price to Cash Flow per share - TTM
--
--
12.05
Price to Free Cash Flow per share - TTM
--
4.31
17.60
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 15, 201990,901-5,269
Aug 31, 201996,170233
Aug 15, 201995,937-179,763
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Imv Inc, formerly known as Immunovaccine Inc is a Canada-based clinical-stage immuno oncology company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
INK Staff's picture
What do insiders prefer: traditional or alternative Healthcare stocks? https://www.canadianinsider.com/featured-report/what-do-insiders-prefer-traditional-or-alternative-healthcare-stocks $HMMJ.CA $WEED.CA $BHC $CGC $ACB.CA $IMV.CA
Nov 09, 2018 11:58 am
INK Staff's picture
What do insiders prefer: traditional or alternative Healthcare stocks? https://www.canadianinsider.com/featured-report/what-do-insiders-prefer-traditional-or-alternative-healthcare-stocks $HMMJ.CA $WEED.CA $BHC $CGC $ACB.CA $IMV.CA
Nov 09, 2018 11:58 am
Ted Dixon's picture
Insiders still buying at ImmunoVaccine. Free INK Research company report for logged in users: https://www.canadianinsider.com/featured-report/insiders-still-buying-immunovaccine $IMV.CA $IBB
May 12, 2017 10:09 am
INK Staff's picture
Insiders still buying at ImmunoVaccine. Free INK Research company report for logged in users: https://www.canadianinsider.com/featured-report/insiders-still-buying-immunovaccine $IMV.CA $IBB
May 12, 2017 10:09 am

Twitter

Search (past week) for $IMV.CA

  • No tweets found

StockTwits